Aguilera X, González C, Apablaza M, Rubilar P, Icaza G, Ramírez-Santana M, Pérez C,
Cortes LJ, Núñez-Franz L, Quezada-Gaete R, Castillo-Laborde C, Correa J, Said M,
Hormazábal J, Vial C, Vial P. 2022. Immunization and SARS-CoV-2 antibody seroprevalence
in a country with high vaccination coverage: lessons from chile. Vaccines 10(7):1002
DOI 10.3390/vaccines10071002.
Assure Tech. 2020. COVID-19 ecotest; antibody rapid detection test. Available at https://
verifydiagnostics.com/wp-content/uploads/2020/10/EU-AssureTech-Rapid-Antibody.pdf
(accessed 22 May 2023).
Awandu SS, Ochieng Ochieng A, Onyango B, Magwanga RO, Were P, Atieno Ochung’ A,
Okumu F, Oloo MA, Katieno JS, Lidechi S, Ogutu F, Awuor D, Kirungu JN, Orata F,
Achieng J, Oure B, Nyunja R, Muok EMO, Munga S, Estambale B. 2022. High seroprevalence
of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and
symptomatic individuals amidst vaccination roll-out in western Kenya. PLOS ONE
17(12):e0272751 DOI 10.1371/journal.pone.0272751.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,
Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
10/15
Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,
Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W,
Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. 2021. Efficacy and safety of
the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine 384(5):403–416
DOI 10.1056/NEJMoa2035389.
Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. 2022. Comparison of SARS-CoV-2 anti-spike
receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1
COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based
study. The Lancet Microbe 3(4):e274–e283 DOI 10.1016/S2666-5247(21)00305-0.
Ben Houmich T, Tali A, Debbagh F, Lamrani Hanchi A, Soraa N. 2022. Seroprevalence of SARSCoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). International
Journal of Immunopathology and Pharmacology 36:3946320221133697
DOI 10.1177/03946320221133697.
Björk J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Inghammar M.
2022. Surveillance of COVID-19 vaccine effectiveness: a real-time case-control study in
southern Sweden. Epidemiology and Infection 150:1–15 DOI 10.1017/S0950268822000425.
Chau NVV, Nguyet LA, Truong NT, Toan LM, Dung NT, Hung LM, Nhan MT, Man DNH,
Ngoc NM, Thao HP, Tu TNH, Mai HK, Hung DT, Ny NTH, Thanh LK, Anh NT,
Hong NTT, Nhu LNT, Yen LM, Choisy M, Thanh TT, Thwaites G, Tan LV. 2022.
Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in vietnamese health-care workers.
The American Journal of Tropical Medicine and Hygiene 106(2):556–561
DOI 10.4269/ajtmh.21-0849.
Chiarella SE, Jenkins SM, Smith CY, Prasad V, Shakuntulla F, Ahluwalia V, Iyer VN, Theel ES,
Joshi AY. 2022. Predictors of seroconversion after coronavirus disease 2019 vaccination. Annals
of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy,
Asthma, & Immunology 129:189–193 DOI 10.1016/j.anai.2022.05.026.
COVID-19 Treatment Guidelines Panel. 2022. Coronavirus disease 2019 (COVID-19) treatment
guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.
nih.gov/ (accessed 13 January 2023).
Cucinotta D, Vanelli M. 2020. WHO declares COVID-19 a pandemic. Acta Bio-Medica: Atenei
Parmensis 91:157–160 DOI 10.23750/abm.v91i1.9397.
Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. 2021. Antibody response to the
inactivated SARS-CoV-2 vaccine among healthcare workers. Indonesia International Journal of
Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases
113:15–17 DOI 10.1016/j.ijid.2021.09.078.
Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. 2022. Antibody response after a
third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of
inactivated SARS-CoV-2 vaccine. International Journal of Infectious Diseases: IJID: Official
Publication of the International Society for Infectious Diseases 118(6):116–118
DOI 10.1016/j.ijid.2022.02.036.
Decarreaux D, Pouquet M, Souty C, Vilcu A-M, Prévot-Monsacre P, Fourié T, Villarroel PMS,
Priet S, Blanché H, Sebaoun J-M, Deleuze J-F, Turbelin C, Werner A, Kochert F,
Grosgogeat B, Rabiega P, Laupie J, Abraham N, Guerrisi C, Noël H, Van der Werf S,
Carrat F, Hanslik T, Charrel R, De Lamballerie X, Blanchon T, Falchi A. 2022.
Seroprevalence of SARS-CoV-2 IgG antibodies and factors associated with SARS-CoV-2 IgG
neutralizing activity among primary health care workers 6 months after vaccination rollout in
France. Viruses 14(5):957 DOI 10.3390/v14050957.
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
11/15
East Java Public Health Office. 2021. Dashboard COVID-19 Jawa Timur. Available at https://
infocovid19.jatimprov.go.id/.
Elangovan D, Hussain SMS, Virudhunagar Muthuprakash S, Devi Periadurai N,
Viswanath Nalankilli A, Volvoikar H, Ramani P, Sivasubramaniam J, Mohanram K,
Surapaneni KM. 2022. Impact of COVID-19 vaccination on seroprevalence of SARS-CoV-2
among the health care workers in a tertiary care centre, South India. Vaccines 10(11):1967
DOI 10.3390/vaccines10111967.
Fonseca MHG, de Souza T de FG, de Carvalho Araújo FM, de Andrade LOM. 2022. Dynamics of
antibody response to CoronaVac vaccine. Journal of Medical Virology 94(5):2139–2148
DOI 10.1002/jmv.27604.
Fulop T, Pawelec G, Castle S, Loeb M. 2009. Immunosenescence and vaccination in nursing home
residents. Clinical Infectious Diseases 48(4):443–448 DOI 10.1086/596475.
Goh YS, Fong S‐W, Rouers A, Chang ZW, Tay MZ, Chavatte J‐M, Zhuo NZ, Hor PX, Loh CY,
Huang Y, Wong JXE, Tan YJ, Lim DRX, Wang B, Ngoh EZX, Salleh SNM, Lee RTC, Pada S,
Sun LJ, Ong DLS, Somani J, Lee ES, Wang C‐I, Leo Y‐S, Lin RTP, Ren EC, Lye DC,
Young BE, Lim PL, Ng LFP, Renia L. 2022. Heterologous booster vaccination with CoronaVac
following prime vaccination with mRNA vaccine. Clinical & Translational Immunology
11(8):e1403 DOI 10.1002/cti2.1403.
Hidayat R, Mustika AP, Avisha F, Djuliannisaa Z, Winari DD, Putri RA, Lisman HM, Davin V,
Fathi GC, Widhani A, Aini MH, Yudhistira Y, Azizah S, Rahmadani M, Istanti ND,
Giantini A. 2022. Evaluation of SARS-CoV-2 antibody response post third dose COVID-19
mRNA vaccination at Universitas Indonesia hospital. Acta Medica Academica 51(2):69–78.
Huang C-F, Jang T-Y, Wu P-H, Kuo M-C, Yeh M-L, Wang C-W, Liang P-C, Wei Y-J, Hsu P-Y,
Huang C-I, Hsieh M-Y, Lin Y-H, Hsiao H-H, Hsu C-M, Huang C-T, Lee C-Y, Chen Y-H,
Chen T-C, Lin K-D, Wang S-H, Wang S-F, Huang J-F, Dai C-Y, Chuang W-L, Yu M-L. 2023.
Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese
cohort. Virology Journal 20(1):112 DOI 10.1186/s12985-023-02056-5.
Indonesian Ministry of Health. 2021. KEPUTUSAN MENTERI KESEHATAN REPUBLIK
INDONESIA NOMOR HK.01.07/MENKES/4638/2021 TENTANG PETUNJUK TEKNIS
PELAKSANAAN VAKSINASI DALAM RANGKA PENANGGULANGAN PANDEMI CORONA
VIRUS DISEASE 2019 (COVID-19). Available at https://peraturan.bpk.go.id/Home/Details/
171640/keputusan-menkes-no-hk0107menkes46382021 (accessed 22 May 2023).
Indonesian Ministry of Health. 2020. SITUASI TERKINI PERKEMBANGAN NOVEL
CORONAVIRUS (COVID-19); Data dilaporkan sampai 30 Desember 2020. Available at https://
infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangancoronavirus-disease-covid-19-31-desember-2020.
Indonesian Ministry of Health. 2022. Tambah Regimen Baru Vaksin Booster, Total Ada 6 Jenis
Vaksin COVID-19 yang Dipakai di Indonesia. Available at https://www.kemkes.go.id/article/
view/22030100001/tambah-regimen-baru-vaksin-booster-total-ada-6-jenis-vaksin-covid-19yang-dipakai-di-indonesia.html (accessed 14 November 2022).
Indonesian Ministry of Health. 2023a. Vaksinasi COVID-19 Nasional. Available at https://vaksin.
kemkes.go.id (accessed 14 November 2022).
Indonesian Ministry of Health. 2023b. SURAT EDARAN NOMOR HK.02.02/C/380/2023
TENTANG VAKSINASI COVID-19 DOSIS BOOSTER KE-2 BAGI KELOMPOK MASYARAKAT
UMUM. Available at https://www.kemkes.go.id/downloads/resources/download/SE/SEVaksinasi-Booster-Masyarakat-Umum.pdf (accessed 22 May 2023).
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
12/15
Jin L, Li Z, Zhang X, Li J, Zhu F. 2022. CoronaVac: a review of efficacy, safety, and
immunogenicity of the inactivated vaccine against SARS-CoV-2. Human Vaccines &
Immunotherapeutics 18(6):2096970 DOI 10.1080/21645515.2022.2096970.
Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B, Pajon R. 2022.
Clinical utility of elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: an exploratory
analysis of the mRNA-1273 phase 1 trial. Frontiers in Immunology 12:798117
DOI 10.3389/fimmu.2021.798117.
Kajanova I, Lukacikova L, Jelenska L, Grossmannova K, Radikova Z, Vlcek M, Klempa B,
Kollar R, Bodova K, Kopacek J, Pastorekova S. 2022. Seroprevalence of SARS-CoV-2 IgG
antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or
vaccination: situation in August 2021. Acta Virologica 65(4):420–432
DOI 10.4149/av_2021_407.
Karamese M, Tutuncu EE. 2022. The effectiveness of inactivated SARS-CoV-2 vaccine
(CoronaVac) on antibody response in participants aged 65 years and older. Journal of Medical
Virology 94(1):173–177 DOI 10.1002/jmv.27289.
Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. 2022. SARS-CoV-2 specific antibody responses
after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Journal of Medical Virology 94(1):39–41 DOI 10.1002/jmv.27350.
Kwetkat A, Heppner HJ. 2020. Comorbidities in the elderly and their possible influence on vaccine
response. Interdisciplinary Topics in Gerontology and Geriatrics 43:73–85
DOI 10.1159/issn.2297-3486.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. 2021. SARS-CoV-2
vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6(1):28
DOI 10.1038/s41541-021-00292-w.
Lau CS, Thundyil J, Oh MLH, Phua SK, Liang YL, Li Y, Huo J, Huang Y, Zhang B, Xu S, Aw TC.
2022. Neutralizing and Total/IgG spike antibody responses following homologous CoronaVac
vs. BNT162b2 vaccination up to 90 days post-booster. Antibodies 11(4):70
DOI 10.3390/antib11040070.
Lippi G, Henry BM, Plebani M. 2021. Anti-SARS-CoV-2 antibodies testing in recipients of
COVID-19 vaccination: why, when, and how? Diagnostics 11(6):941
DOI 10.3390/diagnostics11060941.
Malagón-Rojas J, Mercado-Reyes M, Toloza-Pérez YG, Galindo M, Palma RM, Catama J,
Bedoya JF, Parra-Barrera EL, Meneses X, Barbosa J, Tavera-Rodríguez P, BermúdezForero A, Ospina-Martínez ML. 2022. Comparison of anti-SARS-CoV-2 IgG antibody
responses generated by the administration of Ad26.COV2.S, AZD1222, BNT162b2, or
CoronaVac: longitudinal prospective cohort study in the Colombian population, 2021/2022.
Vaccines 10:1609 DOI 10.3390/vaccines10101609.
Manuhutu R. 2021. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 01 Januari
2021. Available at https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkiniperkembangan-coronavirus-disease-covid-19-01-januari-2021 (accessed 30 November 2022).
Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, Nishimura M,
Lusida MI, Mori Y, Di Gennaro F. 2021. Seroepidemiological study of SARS-CoV-2 infection
in East Java, Indonesia. PLOS ONE 16(5):e0251234 DOI 10.1371/journal.pone.0251234.
Nugraha B, Wahyuni LK, Laswati H, Kusumastuti P, Tulaar AB, Gutenbrunner C. 2020.
COVID-19 pandemic in Indonesia: situation and challenges of rehabilitation medicine in
Indonesia. Acta Medica Indonesiana 52:299–305.
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
13/15
Olliaro P, Torreele E, Vaillant M. 2021. COVID-19 vaccine efficacy and effectiveness-the elephant
(not) in the room. The Lancet Microbe 2(7):e279–e280 DOI 10.1016/S2666-5247(21)00069-0.
Onifade AA, Fowotade A, Rahamon SK, Edem VF, Yaqub SA, Akande OK, Arinola OG. 2023.
Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult
Nigerians. PLOS ONE 18(1):e0280276 DOI 10.1371/journal.pone.0280276.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,
Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV,
Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB,
Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. C4591001 clinical trial
group, safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. The New England
Journal of Medicine 383(27):2603–2615 DOI 10.1056/NEJMoa2034577.
Rahman MM, Masum MHU, Wajed S, Talukder A. 2022. A comprehensive review on COVID-19
vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease
33(1):1–22 DOI 10.1007/s13337-022-00755-1.
Rezaei M, Sadeghi M, Korourian A, Tabarsi P, Porabdollah M, Askari E, Mortaz E,
Mahmoudi S, Marjani M, Velayati AA. 2021. Comparative evaluation of SARS-CoV-2 IgG
assays against nucleocapsid and spike antigens. Human Antibodies 29(2):109–113
DOI 10.3233/HAB-210440.
Salari N, Vepa A, Daneshkhah A, Darvishi N, Ghasemi H, Khunti K, Mohammadi M. 2022.
Efficacy of COVID-19 vaccines by race and ethnicity. Public Health 208(3):14–17
DOI 10.1016/j.puhe.2022.04.009.
Santi T, Samakto BD, Kamarga L, Hidayat FK, Hidayat F. 2021. Factors associated with SARSCoV-2 antibody titer after sinovac vaccination among health care workers. Acta Medica
Indonesiana 53:374–384.
Shah MM, Spencer BR, Feldstein LR, Haynes JM, Benoit TJ, Saydah SH, Groenewold MR,
Stramer SL, Jones JM. 2022. Occupations associated with severe acute respiratory syndrome
coronavirus 2 infection and vaccination, US blood donors, may 2021–december 2021. Clinical
Infectious Diseases 76(7):1285–1294 DOI 10.1093/cid/ciac883.
Sinto R, Utomo D, Suwarti, Nelwan EJ, Surendra H, Natasha C, Fransiska, Theresia D,
Ranitria AF, Subekti D, Nuraeni N, Handayani W, Rahardjani M, Baird JK, Dunachie S,
Shankar AH, Hamers RL. 2023. Antibody responses and reactogenicity of a heterologous,
full-dose messenger RNA-1273 booster in heavily SARS-CoV-2-exposed CoronaVac-vaccinated
health-care workers in Indonesia: a real-world observational study. The American Journal of
Tropical Medicine and Hygiene 108(1):115–123 DOI 10.4269/ajtmh.22-0256.
Song C, Li Z, Li C, Huang M, Liu J, Fang Q, Cao Z, Zhang L, Gao P, Nie W, Luo X, Kang J, Xie S,
Lyu J, Zhu X. 2022. SARS-CoV-2: the monster causes COVID-19. Frontiers in Cellular and
Infection Microbiology 12:835750 DOI 10.3389/fcimb.2022.835750.
Tan CS, Noni V, Melina WUHU, Abdorahman US, Bimbang JN, Malik NMA, Hossen ME,
Rahman MM, Su’ut L, Said A, Chen C, Sepop B, Samat MA, Chew JCM, Mamora D, Tan SK.
2022. Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia. Scientific
Reports 12(1):15665 DOI 10.1038/s41598-022-19776-3.
Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY,
Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R,
Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A, Halmos B.
2021. Seroconversion rates following COVID-19 vaccination among patients with cancer.
Cancer Cell 39(8):1081–1090.e2 DOI 10.1016/j.ccell.2021.06.002.
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
14/15
Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P,
Indevuyst C, Depypere M, Desmet S, André E, Van Ranst M, Lagrou K, Vermeersch P. 2020.
Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four
automated immunoassays and three ELISAs. Clinical Microbiology and Infection 26(11):1557.
e1–1557.e7 DOI 10.1016/j.cmi.2020.07.038.
Varghese S, Mateethra G, George G, Chandran V, John G, Varghese L, Mammen N, Vinayak V.
2022. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine
in Central Kerala. Indian Journal of Medical Research 155(5&6):499–504
DOI 10.4103/ijmr.ijmr_1917_21.
Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D,
Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, HueyTubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J,
Xu J, Colbert RA, Patel R, Dizon J, Unson-O’Brien C, Shimeliovich I, Gazumyan A,
Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. 2021.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature
592(7855):616–622 DOI 10.1038/s41586-021-03324-6.
Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J,
Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI,
Crook DW, Peto TEA, Pouwels KB, Eyre DW, Walker AS, Thomas T, Black R, Felton A,
Crees M, Jones J, Lloyd L, Sutherland E, Pritchard E, Vihta K-D, Doherty G, Kavanagh J,
Chau KK, Hatch SB, Ebner D, Ferreira LM, Christott T, Dejnirattisai W, Mongkolsapaya J,
Cameron S, Tamblin-Hopper P, Wolna M, Brown R, Cornall R, Screaton G, Lythgoe K,
Bonsall D, Golubchik T, Fryer H, Cox S, Paddon K, James T, House T, Robotham J,
Birrell P, Jordan H, Sheppard T, Athey G, Moody D, Curry L, Brereton P, Jarvis I,
Godsmark A, Morris G, Mallick B, Eeles P, Hay J, VanSteenhouse H, Lee J. 2021. Antibody
responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United
Kingdom. Nature Microbiology 6(9):1140–1149 DOI 10.1038/s41564-021-00947-3.
Wisnewski AV, Campillo Luna J, Redlich CA. 2021. Human IgG and IgA responses to
COVID-19 mRNA vaccines. PLOS ONE 16(6):e0249499 DOI 10.1371/journal.pone.0249499.
World Health Organization. 2022. Coronavirus disease (COVID-19): vaccines. Available at
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/qa-detail/coronavirus-disease-(covid-19)-vaccines (accessed 16 December 2022).
Megasari et al. (2023), PeerJ, DOI 10.7717/peerj.16142
15/15
...
論文の公開元へ
